Statistical Trends in Pharmaceutical Research for Poor Countries
Introducing patent rights in developing country markets might stimulate greater R and D investment targeting their specific health needs â€“ areas long neglected. This paper examines this argument using statistical data and survey evidence. We identify a set of diseases where 99 per cent of the burden is estimated to fall in lower income countries. Because science gaps and market potential will influence R and D priorities, this group is broke into a subset that already have low-cost and effect treatments, and those that to not.
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Wesley M. Cohen & Richard R. Nelson & John P. Walsh, 2000.
"Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not),"
NBER Working Papers
7552, National Bureau of Economic Research, Inc.
- Wesley M Cohen & Richard R Nelson & John P Walsh, 2003. "Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (Or Not)," Levine's Working Paper Archive 618897000000000624, David K. Levine.
- Lanjouw, Jean O. & Cockburn, Iain M., 2001. "New Pills for Poor People? Empirical Evidence after GATT," World Development, Elsevier, vol. 29(2), pages 265-289, February.
When requesting a correction, please mention this item's handle: RePEc:ess:wpaper:id:2308. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Padma Prakash)
If references are entirely missing, you can add them using this form.